CADL — Candel Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1841387 ·
Last close
$9.94
Market Cap
$760.59M
52W High
$14.00
52W Low
$4.35
ADV30
1,111,766
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -26,724,000 | -38,905,000 | 208,149,000 | 201,565,000 | 82,019,000 |
| Mar 2026 | 0 | — | -16,262,000 | -8,861,000 | 201,920,000 | 194,834,000 | 63,891,000 |
| Dec 2025 | 0 | — | -15,663,000 | -29,496,000 | 125,195,000 | 119,731,000 | 73,273,000 |
| Sep 2025 | 0 | — | -13,207,000 | -11,269,000 | 93,598,000 | 86,963,000 | 13,474,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-47,732,000
Investing CF
$-1,232,000
Financing CF
$151,783,000
CapEx
$-1,259,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.98
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-239,248,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-51,045,000
Pretax Income TTM
$-54,422,000
Interest Exp TTM
$3,377,000
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -48,177,000 | -38,182,000 | 125,195,000 | 73,273,000 | 51,922,000 | -38,311,000 |
| Dec 2024 | 0 | -33,371,000 | -55,177,000 | 106,866,000 | 40,539,000 | 66,327,000 | -27,023,000 |
| Dec 2023 | 0 | -38,391,000 | -37,939,000 | 41,201,000 | 28,456,000 | 12,745,000 | -34,244,000 |
| Dec 2022 | 125,000 | -34,674,000 | -18,794,000 | 77,691,000 | 29,977,000 | 47,714,000 | -31,419,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-54,422,000
OpCashFlow TTM
—
Assets (Latest)
$201,920,000
Forward EPS
$-0.62
Max Pain — expiry 2027-01-15
max pain strike: $8.00 · spot: $9.94 · call oi: 5,192 · put oi: 1,474
Expected Move to 2027-01-15:
±$3.50
(35.21%) —
implied range
$6.44 –
$13.44
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ATTO | Attovia Therapeutics, Inc. | $740.01M | $16.21 | — |
| SLDB | Solid Biosciences Inc. | $736.64M | $6.87 | — |
| FDMT | 4D Molecular Therapeutics, Inc. | $736.41M | $13.33 | — |
| PRME | Prime Medicine, Inc. | $723.69M | $3.99 | — |
| DNA | Ginkgo Bioworks Holdings, Inc. | $719.99M | $13.00 | — |
News headlines (Yahoo Finance, 1h cache)
Candel Therapeutics to Present at the SITC 2026 Annual Meeting
2026-10-02 13:00 · Yahoo
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-01 20:05 · Yahoo
CADL Slips Despite Encouraging Prostate Cancer Drug Data — Retail Believes Stock Is ‘Clearly A Buy And Hold’
2026-09-30 15:00 · Yahoo
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Can
2026-09-30 12:30 · Yahoo
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
2026-09-30 12:05 · Yahoo
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
2026-09-10 12:05 · Yahoo
Candel Therapeutics to Present at September Investor Conferences
2026-08-26 12:05 · Yahoo
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4
2026-08-13 19:27 · Yahoo
CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity
2026-08-12 19:08 · Yahoo
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up
2026-08-12 17:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.